Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125924611 | 12592461 | 1 | I | 20160715 | 20160726 | 20160726 | EXP | US-ACS-000427 | ACS DOBFAR | WOODS RJ, READ AF. CLINICAL MANAGEMENT OF RESISTANCE EVOLUTION IN A BACTERIAL INFECTION: A CASE STUDY. EVOLUTION, MEDICINE AND PUBLIC HEALTH. 2015;2015(1) : 281-288 ARTICLE NUMBER EOV025 | 56.00 | YR | F | Y | 0.00000 | 20160726 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125924611 | 12592461 | 1 | PS | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 2 | SS | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 3 | SS | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 4 | SS | MEROPENEM. | MEROPENEM | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 5 | SS | MEROPENEM. | MEROPENEM | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 6 | SS | MEROPENEM. | MEROPENEM | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 7 | SS | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 8 | SS | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 9 | SS | MOXIFLOXACIN. | MOXIFLOXACIN | 1 | Unknown | 0 | |||||||||||
| 125924611 | 12592461 | 10 | SS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Unknown | 0 | |||||||||||
| 125924611 | 12592461 | 11 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Unknown | 0 | |||||||||||
| 125924611 | 12592461 | 12 | SS | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
| 125924611 | 12592461 | 13 | SS | VANCOMYCIN | VANCOMYCIN | 1 | Intravenous (not otherwise specified) | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125924611 | 12592461 | 1 | Infection |
| 125924611 | 12592461 | 2 | Infection |
| 125924611 | 12592461 | 3 | Infection |
| 125924611 | 12592461 | 4 | Infection |
| 125924611 | 12592461 | 5 | Infection |
| 125924611 | 12592461 | 6 | Enterobacter infection |
| 125924611 | 12592461 | 7 | Infection |
| 125924611 | 12592461 | 8 | Infection |
| 125924611 | 12592461 | 9 | Infection |
| 125924611 | 12592461 | 10 | Infection |
| 125924611 | 12592461 | 11 | Staphylococcal infection |
| 125924611 | 12592461 | 12 | Infection |
| 125924611 | 12592461 | 13 | Infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125924611 | 12592461 | DE |
| 125924611 | 12592461 | HO |
| 125924611 | 12592461 | OT |
| 125924611 | 12592461 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125924611 | 12592461 | Drug ineffective | |
| 125924611 | 12592461 | Pathogen resistance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |